...
首页> 外文期刊>Infection >Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI).
【24h】

Design of a surveillance system of antibiotic use and bacterial resistance in German intensive care units (SARI).

机译:德国重症监护病房(SARI)抗生素使用和细菌耐药性监测系统的设计。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Data on antibiotic consumption and bacterial resistance are important for benchmarking, ensuring quality of antibiotic treatment and helping to understand the relationship between the use of antibiotics and the emergence of resistance. METHODS: The SARI project is an ecological study that has established laboratory-based surveillance in German intensive care units (ICU). Resistance rates of 13 sentinel pathogens are reported and certain alert organisms are sent for genotyping and retesting of antimicrobial resistance. RESULTS: The project, initiated in February 2000, now includes 35 ICUs generating a total of 266,013 patient days, 354,356 defined daily doses (DDD) and providing susceptibility data on 21,354 isolates. Pooled antibiotic usage density (AD = DDD/1,000 patient days) was highest for penicillins with lactamase inhibitor (AD 338.3) followed by quinolones (AD 155.5) and second-generation cephalosporins (AD 124.6). Total AD was calculated as 1,337 DDD/1,000 patient days. Resistance rates (RR) for laboratories testing according to the German Industrial Standard (DIN) were 19.3% for methicillin-resistant Staphylococcus aureus (MRSA), 9.5% for ciprofloxacin-resistant Escherichia coli and 25.4% for imipenem-resistant Pseudomonas aeruginosa. 40% of the laboratories did not identify the extended spectrum beta lactamase production of a Klebsiella pneumoniae strain. CONCLUSION: Focusing on German ICUs, the SARI surveillance system provides a concept that produces a benchmark for the link between antibiotic resistance and consumption.
机译:背景:关于抗生素消耗和细菌耐药性的数据对于基准测试,确保抗生素治疗质量以及帮助理解抗生素使用与耐药性出现之间的关系非常重要。方法:SARI项目是一项生态研究,已在德国重症监护病房(ICU)中建立了基于实验室的监视。报告了13种前哨病原体的耐药率,并派出了某些警戒性生物进行基因分型和抗菌素耐药性的重新测试。结果:该项目于2000年2月启动,现在包括35个ICU,总共产生266,013个患者日,354,356个确定的日剂量(DDD)并提供21354个分离株的药敏性数据。含内酰胺酶抑制剂的青霉素(AD 338.3),其次是喹诺酮类药物(AD 155.5)和第二代头孢菌素(AD 124.6)的合并抗生素使用密度(AD = DDD / 1,000患者天)最高。总AD计算为1,337 DDD / 1,000患者日。根据德国工业标准(DIN)的实验室测试,耐甲氧西林的金黄色葡萄球菌(MRSA)的耐药率(RR)为19.3%,耐环丙沙星的大肠杆菌为9.5%,耐亚胺培南的铜绿假单胞菌为25.4%。 40%的实验室没有发现肺炎克雷伯菌的广谱β-内酰胺酶产物。结论:以德国的ICU为重点,SARI监视系统提供了一个概念,可为抗生素耐药性与消费之间的联系提供基准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号